Elanco Q1 2026 Revenue Outlook Amid Guidance Updates
This discussion analyzes Elanco's revenue outlook for Q1 2026 based on recent guidance updates and compares it with sector trends.
Read postDetailed company information
Elanco Animal Health, a firm dedicated to animal well-being, creates, produces, and commercializes a diverse array of solutions for both companion animals and livestock. For household pets, the company provides preventative health solutions, including parasiticides and vaccinations, designed to guard against common ailments like worms, fleas, and ticks, with notable brands such as Seresto, Advantage, Advantix, and Advocate. Additionally, Elanco supplies therapeutic treatments for canine and feline conditions including pain, osteoarthritis, ear infections, cardiovascular issues, and dermatological problems, marketed under labels like Galliprant and Claro. Its portfolio for agricultural animals encompasses vaccines, antibiotics, parasiticides, and other essential products for poultry and aquaculture farming. This segment also features nutritional supplements such as enzymes, probiotics, and prebiotics to support animal health and growth. Furthermore, the company offers a comprehensive suite of products for ruminant and swine operations, comprising vaccines, antibiotics, implants, and parasiticides, often recognized by brands like Rumensin and Baytril. Elanco distributes its offerings through various channels, including independent distributors, veterinary clinics, and a broad spectrum of farm animal producers, from cattle and dairy farms to pig, poultry, and aquaculture enterprises. Established in 1954, Elanco Animal Health Incorporated maintains its corporate headquarters in Greenfield, Indiana.
Last Updated: Sep 2026
Earnings Transcript for 2026 - Q2Released: Aug 05, 2026
Earnings Transcript for 2026 - Q1Released: May 06, 2026
Earnings Transcript for 2025 - Q4Released: Feb 24, 2026
Earnings Transcript for 2025 - Q3Released: Nov 05, 2025
Earnings Transcript for 2025 - Q2Released: Aug 07, 2025
Earnings Transcript for 2025 - Q1Released: May 07, 2025
Earnings Transcript for 2024 - Q4Released: Feb 25, 2025
Earnings Transcript for 2024 - Q3Released: Nov 07, 2024
Earnings Transcript for 2024 - Q2Released: Aug 08, 2024
Earnings Transcript for 2024 - Q1Released: May 08, 2024
Earnings Transcript for 2023 - Q4Released: Feb 26, 2024
Earnings Transcript for 2023 - Q3Released: Nov 07, 2023
Earnings Transcript for 2023 - Q2Released: Aug 07, 2023
Earnings Transcript for 2023 - Q1Released: May 09, 2023
Earnings Transcript for 2022 - Q4Released: Feb 21, 2023
Earnings Transcript for 2022 - Q3Released: Nov 08, 2022
Earnings Transcript for 2022 - Q2Released: Aug 08, 2022
Earnings Transcript for 2022 - Q1Released: May 09, 2022
Earnings Transcript for 2021 - Q4Released: Feb 24, 2022
Earnings Transcript for 2021 - Q3Released: Nov 05, 2021
Earnings Transcript for 2021 - Q2Released: Aug 09, 2021
Earnings Transcript for 2021 - Q1Released: May 11, 2021
Earnings Transcript for 2020 - Q4Released: Feb 24, 2021
Earnings Transcript for 2020 - Q3Released: Nov 09, 2020
SIGA SIGA Technologies, Inc.
This discussion analyzes Elanco's revenue outlook for Q1 2026 based on recent guidance updates and compares it with sector trends.
Read postElanco's Q1 2026 revenue growth exceeded expectations, with a 10% organic constant-currency increase, prompting a positive outlook and upgraded full-year growth guidance.
Read post